InMode Ltd.

InMode Ltd., headquartered in Yokneam, Israel, is the global leader in minimally invasive RF aesthetic and surgical solutions. With $370.5 million in 2025 revenue and a 46% GAAP operating margin — the highest in the aesthetics industry — InMode has defined the category of subdermal adipose remodeling through its Morpheus8, BodyTite, and FaceTite platforms.

1. Financial & Market Performance

InMode generated $370.5 million in 2025 revenue, reflecting a 6% year-over-year decline amid macroeconomic-driven softness in the aesthetics device market. However, Q1 2026 performance of $82 million (+5% sequentially) signals demand stabilization. The company's extraordinary 46% GAAP operating margin — the highest in the medical aesthetics industry — reflects its vertically integrated, asset-light business model. Morpheus8 has become one of the most-demanded aesthetic devices globally, with applications spanning facial rejuvenation, acne scarring, and body contouring. North America represents approximately 65% of total revenue.

2. Manufacturing & Supply Chain

InMode's vertically integrated manufacturing is based in Yokneam, Israel, with in-house design, engineering, and assembly capabilities. This integration enables rapid product iteration cycles and industry-leading gross margins, but exposes the business to Middle East geopolitical risk. In 2025, InMode invested in supply chain diversification, establishing secondary assembly capabilities outside Israel and building strategic component inventories. The company's direct sales model in key markets (US, Canada, Europe) and distributor partnerships in emerging regions provide balanced geographic and channel exposure.

3. Key Developments & Strategic Outlook

InMode is expanding beyond core RF platforms into new modalities: hands-free body contouring, women's health (EmpowerRF, EnvisionRF), and surgical applications. The company is investing in AI-powered treatment planning and consumables-based recurring revenue models. Key challenges include GLP-1 medication impact on body contouring demand, emerging competition from Chinese and Korean manufacturers, and Israeli geopolitical instability. However, InMode's technological leadership, extraordinary profitability, and strong balance sheet provide substantial resilience. The Q1 2026 recovery suggests that fundamental demand for minimally invasive RF treatments remains intact.